about
Middle East respiratory syndrome coronavirus: five years later.Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.Current understanding of middle east respiratory syndrome coronavirus infection in human and animal modelsA Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
MERS-CoV spike protein: a key target for antivirals.
@ast
MERS-CoV spike protein: a key target for antivirals.
@en
type
label
MERS-CoV spike protein: a key target for antivirals.
@ast
MERS-CoV spike protein: a key target for antivirals.
@en
prefLabel
MERS-CoV spike protein: a key target for antivirals.
@ast
MERS-CoV spike protein: a key target for antivirals.
@en
P2093
P2860
P50
P1476
MERS-CoV spike protein: a key target for antivirals.
@en
P2093
P2860
P304
P356
10.1080/14728222.2017.1271415
P407
P577
2016-12-11T00:00:00Z